Sanara MedTech Q2 Revenue Misses, Swings to Loss Amid Pending MiMedx Acquisition
SMTI has more than doubled off its 52-week low of $16.047 on elevated volume (2.4× avg).
Summary
Sanara MedTech's Q2 revenue of $28.1M missed estimates, and the company swung to a loss. The pending MiMedx acquisition at $35.00 per share remains the dominant narrative.
Key Events · Earnings and Guidance · SMTI
-
Q2 Revenue Miss
Net revenue of $28.1M grew 9% YoY but fell short of the $28.95M consensus estimate.
-
Swung to Net Loss
Net loss from continuing operations was $0.4M, or $0.05 per diluted share, compared to net income of $0.5M in Q2 2025, driven by higher SG&A and interest expenses.
-
Adjusted EBITDA Growth
Adjusted EBITDA rose to $5.0M from $4.7M in Q2 2025, reflecting revenue growth offset by higher operating costs.
-
Pending MiMedx Acquisition
The results come two weeks after the announcement of a $35.00 per share cash-and-stock acquisition by MiMedx Group, which remains subject to shareholder and regulatory approvals.
Analysis · SMTI · Industrial Applications And Services
Sanara MedTech's second-quarter revenue reached $28.1 million, a 9% year-over-year increase that nonetheless fell short of the $28.95 million consensus. The company swung to a $0.4 million net loss from continuing operations, pressured by higher SG&A and interest expenses. Adjusted EBITDA improved to $5.0 million. These results arrive against the backdrop of the pending acquisition by MiMedx Group for $35.00 per share in cash and stock, announced July 29, 2026. While the earnings miss and loss may dampen sentiment, the acquisition provides a valuation floor. Management also reiterated that the OsStic bone void filler remains on track for a Q1 2027 launch.
At the time of this filing, SMTI was trading at $34.12 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $316.1M. The 52-week trading range was $16.05 to $35.95. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.